Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Horm Metab Res ; 40(11): 752-9, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18711692

RESUMO

Tubular damage is a major feature in the development of diabetic nephropathy. This study investigates the effects of the thiazolidindione rosiglitazone on angiotensin II and advanced glycation end product-induced tubular activation in human proximal tubular epithelial cells IN VITRO. Angiotensin II and advanced glycation end products, both induced a dose-dependent sustained activation of the redox-sensitive transcription factor, Nuclear Factor KAPPA B (NF-kappaB). Nuclear translocation of NF-kappaB was evident already after one hour and persistent for more than four days. Co-incubation of proximal tubular epithelial cells with rosiglitazone significantly reduced angiotensin II and advanced glycation end product-mediated generation of reactive oxygen species, angiotensin II-dependent advanced glycation end product formation, NF-kappaB activation, and NF-kappaB-dependent pro inflammatory gene expression. Most importantly, rosiglitazone effects on NFkappaB activation were maximal at later time points, indicating that rosiglitazone treatment confers long lasting renoprotective effects.


Assuntos
Angiotensina II/análise , Produtos Finais de Glicação Avançada/farmacologia , Hipoglicemiantes/farmacologia , Túbulos Renais Proximais/metabolismo , NF-kappa B/metabolismo , Tiazolidinedionas/farmacologia , Angiotensina II/farmacologia , Angiotensina II/fisiologia , Núcleo Celular/metabolismo , Células Cultivadas , Nefropatias Diabéticas/prevenção & controle , Células Epiteliais/química , Células Epiteliais/metabolismo , Expressão Gênica , Humanos , Túbulos Renais Proximais/química , Estresse Oxidativo , Receptor para Produtos Finais de Glicação Avançada , Receptores Imunológicos/genética , Rosiglitazona , Tirosina/análogos & derivados , Tirosina/biossíntese
2.
Exp Clin Endocrinol Diabetes ; 112(3): 135-41, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15052533

RESUMO

Several polymorphisms have been identified in the RAGE-promoter region that might modulate the outcome of disease. Here we analyse the association of a 63bp deletion (delta63) spanning from bp - 407 to bp - 345 with diabetic nephropathy. The deletion was determined using the polymerase chain reaction (PCR) in a cross-sectional study with 1087 patients with type 1 diabetes (n = 559) and type 2 diabetes (n = 528). 475 patients with osteoporosis served as disease independent control. The prevalence of the heterozygous genotype did not significantly differ between the three groups (type 1: 2.15 %, type 2: 2.27 %, controls: 1.47 %), indicating that heterozygous delta63 is not related to the manifestation of diabetes. Homozygous carriers were not identified in this study. The heterozygous delta63 genotype, was associated with a reduced prevalence of diabetic nephropathy in patients with type 2 diabetes (OR = 0.06; 95 % CI: [0.05, 0.07]), but not in patients with type 1 (OR = 1.49; 95 % CI: [1.14, 1.94]). We conclude, that patients with type 2 diabetes and the 63bp deletion in the promoter of RAGE seem to be protected from diabetic nephropathy. The observed difference between type 1 and type 2 diabetes might point to diverse pathomechanisms of nephropathy in both types of diabetes.


Assuntos
Diabetes Mellitus Tipo 2/genética , Nefropatias Diabéticas/genética , Regiões Promotoras Genéticas/genética , Deleção de Sequência , Diabetes Mellitus Tipo 1/genética , Nefropatias Diabéticas/prevenção & controle , Genótipo , Humanos , Reação em Cadeia da Polimerase , Polimorfismo Genético/genética , Polimorfismo Conformacional de Fita Simples , Prevalência , Receptor para Produtos Finais de Glicação Avançada/genética , Valores de Referência , Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...